Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 1, 2012, Pages 55-60

  Bates, David ^a   Bartholomé, Emmanuel ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Tivoli Hospital   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; NATALIZUMAB; PLACEBO;

ADULT; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SENSITIVITY ANALYSIS;

EID: 84155165285     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2011-300279     Document Type: Article

References (28)

1. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7:615-25.
2. Bakshi R, Minagar A, Jaisani Z, et al. Imaging of multiple sclerosis: role in neurotherapeutics. NeuroRx 2005;2:277-303. (Pubitemid 40471438)
3. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-9. (Pubitemid 23333237)
4. Miller DH, Rudge P, Johnson G, et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 1988;111:927-39.
5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6. (Pubitemid 41746873)
6. Gauthier SA, Glanz BI, Mandel M, et al. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci 2009;284:116-19.
7. Barkhof F, Bruck W, De Groot CJ, et al. Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003;60:1073-81. (Pubitemid 36975794)
8. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009;65:268-75.
9. Oreja-Guevara C, Charil A, Caputo D, et al. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsinge-emitting multiple sclerosis. Arch Neurol 2006;63:736-40.
10. Rovaris M, Rodegher M, Comi G, et al. Correlation between MRI and short-term clinical activity in multiple sclerosis: comparison between standard-and triple-dose Gd-enhanced MRI. Eur Neurol 1999;41:123-7. (Pubitemid 29176558)
11. Berger T. Current therapeutic recommendations in multiple sclerosis. J Neurol Sci 2009;287(Suppl 1):S37-45.
12. Petkau J, Reingold SC, Held U, et al. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 2008;14:770-8.
13. Feigin A. Evidence from biomarkers and surrogate endpoints. NeuroRx 2004;1:323-30. (Pubitemid 46589361)
14. Daumer M, Neuhaus A, Morrissey S, et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009;72:705-11.
15. Sormani MP, Stubinski B, Cornelisse P, et al. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler 17:541-9.
16. Zivadinov R. Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials. Methods Find Exp Clin Pharmacol 2009;31:29-40.
17. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
18. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
19. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009;8:254-60.
20. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390-401. (Pubitemid 46659091)
21. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52. (Pubitemid 14237132)
22. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;69:1391-403. (Pubitemid 47511460)
23. Dalton CM, Miszkiel KA, Barker GJ, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004;251:407-13. (Pubitemid 38501297)
24. Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006;253:287-93.
25. Río J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008;14:479-84.
26. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56:548-55. (Pubitemid 39319345)
27. Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs. Mult Scler 17:630-3.
28. Greenberg B, Frohman EM. Defining success in multiple sclerosis: treatment failures and nonresponders. Adv Stud Med 2008;8:274-83.